Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > NBOC increases their holding by 117 per cent

<< Previous

Bullboard Posts

Next >>

Comment by scarlet1967on Jan 26, 2023 8:57pm

105 Views

Post# 35249252

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:NBOC increases their holding by 117 per cent

No it's not just to clarify what has been going on the way I see it.

palinc2000 wrote:
I hope that is not a reply to my last 2 posts....I was just being sarcastic !!!

scarlet1967 wrote:

They have in house scientists with PHD/post doctoral/ M.Sc.etc. degrees and multi decade expertise in Biochemistry / Pharmacology/Medicinal Chemistry/liquid chromatography human metabolomics…

Add to that UQAM team including professor Richard Bliveau. Now they added external

scientists to assist with the sub analysis of the human data thus far.

Point is even excluding Dr. Rothenberg they have a bunch of scientists some hired as early as 2021 and some as late as second half of 2022 including oncology project managers . Not to mention the trial had to be approved by FDA’s own advisory scientific panel and run by experienced oncologist in various hospitals. So I don’t think all those folks and their assessments and reassessments have less value or credibility on the overall potential design/best outcome of the study than one poster on this board. Can all these folks be wrong and JMF’s contradicting messages be correct???